Clinical trial · Observational
Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
For many years, researchers and doctors have studied different kinds of treatments to improve the survival of men with testicular cancer. However, recent research has shown that many years later, men who had testicular cancer appear to be at higher risk for developing heart disease (heart attack or heart failure), especially if they received chemotherapy. Since these studies were done many years after men received treatment, there was no way to know if other factors contributed to the health problems they experienced. This study is being done because it would be helpful to study heart function and cardiovascular disease risk factors of men who have been diagnosed with testicular cancer, before and after they receive chemotherapy treatment compared to men who receive treatment with surgery alone.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-seminomatous | Testicular Neoplasm | PROBABILISTIC | 0.70 |
| Seminoma | Seminoma | ONTOLOGY_EXACT | 0.98 |
| Testicular Cancer | Malignant Testicular Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- 1
- description
- Testicular cancer patients who have received surgery and are scheduled for surveillance
- label
- 2
- description
- Testicular cancer patients who have received surgery and are scheduled for chemotherapy
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * surgery and surveillance * surgery and multi-cycle chemotherapy * both good and intermediate prognosis seminoma and non-seminomatous germ cell testicular tumors * Karnofsky performance index \> 70% * no contraindications to cardiopulmonary testing Exclusion Criteria: * documented cardiovascular disease or evidence of myocardial ischemia on the incremental exercise (VO2peak) test.
References
Publications (0)
Data not yet available